aThe Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 study is a randomized, open-label, multicenter trial aimed to test the hypothesis that a strategy based on prasugrel plus bivalirudin is superior to a strategy based on clopidogrel plus unfractionated heparin in terms of net clinical outcome...
Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I)BackgroundThe effect of prasugrel in terms of the prevention of recurrence of ischaemic stroke is unknown. We investigated the non-inferiority of ...
In the DOVE trial with prasugrel, differences between treatment arms in VOC rate started to emerge after the first 3 months of treatment (Heeney et al, 2016). Another potential limitation of HESTIA2 is the relatively small number of patients per group. In conclusion, in...
[6]. The P2Y12 receptor plays a crucial role in thrombus ormation and stabi- lization: the receptor augments the activating signal or platelet aggregation and promotes platelet release reaction [7]. Ticlopidine, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel and BX 667 are antagonists o ...
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 来自 Semantic Scholar 喜欢 0 阅读量: 34 作者: